Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Protalix BioTherapeutics (PLX) over the last 17 years, with Q1 2025 value amounting to $2.0 million.

  • Protalix BioTherapeutics' Current Deferred Revenue fell 8188.24% to $2.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.0 million, marking a year-over-year decrease of 8188.24%. This contributed to the annual value of $13.2 million for FY2022, which is 5412.87% up from last year.
  • As of Q1 2025, Protalix BioTherapeutics' Current Deferred Revenue stood at $2.0 million, which was down 8188.24% from $12.7 million recorded in Q2 2024.
  • In the past 5 years, Protalix BioTherapeutics' Current Deferred Revenue ranged from a high of $18.1 million in Q2 2021 and a low of $2.0 million during Q1 2025
  • Over the past 5 years, Protalix BioTherapeutics' median Current Deferred Revenue value was $11.8 million (recorded in 2022), while the average stood at $11.0 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Current Deferred Revenue plummeted by 8653.62% in 2021 and then surged by 36097.66% in 2022.
  • Protalix BioTherapeutics' Current Deferred Revenue (Quarter) stood at $8.5 million in 2021, then soared by 54.13% to $13.2 million in 2022, then fell by 10.53% to $11.8 million in 2023, then increased by 7.68% to $12.7 million in 2024, then plummeted by 84.25% to $2.0 million in 2025.
  • Its Current Deferred Revenue stands at $2.0 million for Q1 2025, versus $12.7 million for Q2 2024 and $11.0 million for Q1 2024.